Please sign in to follow a disease.

Sclerosing cholangitis

MONDO:0018646

A chronic, autoimmune inflammatory liver disorder characterized by narrowing and scarring of the lumen of the bile ducts. It is often seen in patients with ulcerative colitis. Signs and symptoms include jaundice, fatigue, and malabsorption. It may lead to cirrhosis and liver failure.

Also known as: Primary sclerosing cholangitis, primary sclerosing cholangitis (PSC), sclerosing cholangitis, sclerosing cholangitis (disease)

60 clinical trials for this condition and its sub-types, 3 tagged with Sclerosing cholangitis itself.

Follow this condition to get notified about new trials

Where it sits in the disease tree

Browse by category →

Part of

↑ Cholangitis (139)

Sub-types of Sclerosing cholangitis

Primary sclerosing cholangitis 54 trials
1 sub-type
- Nephropathy, progressive tubulointerstitial, with cholestatic liver disease 0 trials
Secondary sclerosing cholangitis 2 trials
IgG4-related sclerosing cholangitis 0 trials
Isolated neonatal sclerosing cholangitis 0 trials
Neonatal ichthyosis-sclerosing cholangitis syndrome 0 trials

Including sub-types (60) Tagged with Sclerosing cholangitis (3)

Trials to join now! 1 Not yet finished but already full! 1 Completed 1

Can a new drug outperform standard care for a rare liver disease in teens?

Disease control Cancelled

This phase 2 trial is testing whether an experimental drug called HTD1801 can improve liver health in adolescents with primary sclerosing cholangitis (PSC), a rare disease that damages the bile ducts. Participants will receive either HTD1801 or the standard treatment, ursodeoxych…

Phase 2 • Sponsor: HighTide Therapeutics (Hong Kong) Limited • Aim: Disease control

Last updated Aug 14, 2026 00:00 UTC

Sclerosing cholangitis

Where it sits in the disease tree

Can a new drug outperform standard care for a rare liver disease in teens?